Literature DB >> 19753479

The effects of nitric oxide on the immune system during Trypanosoma cruzi infection.

Fredy R S Gutierrez1, Tiago W P Mineo, Wander R Pavanelli, Paulo M M Guedes, João S Silva.   

Abstract

Trypanosoma cruzi infection triggers substantial production of nitric oxide (NO), which has been shown to have protective and toxic effects on the host's immune system. Sensing of trypomastigotes by phagocytes activates the inducible NO-synthase (NOS2) pathway, which produces NO and is largely responsible for macrophage-mediated killing of T. cruzi. NO is also responsible for modulating virtually all steps of innate and adaptive immunity. However, NO can also cause oxidative stress, which is especially damaging to the host due to increased tissue damage. The cytokines IFN-gamma and TNF-alpha, as well as chemokines, are strong inducers of NOS2 and are produced in large amounts during T. cruzi acute infection. Conversely, TGF-beta and IL-10 negatively regulate NO production. Here we discuss the recent evidence describing the mechanisms by which NO is able to exert its antimicrobial and immune regulatory effects, the mechanisms involved in the oxidative stress response during infection and the implications of NO for the development of therapeutic strategies against T. cruzi.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19753479     DOI: 10.1590/s0074-02762009000900030

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  36 in total

1.  Intraphagosomal peroxynitrite as a macrophage-derived cytotoxin against internalized Trypanosoma cruzi: consequences for oxidative killing and role of microbial peroxiredoxins in infectivity.

Authors:  María Noel Alvarez; Gonzalo Peluffo; Lucía Piacenza; Rafael Radi
Journal:  J Biol Chem       Date:  2010-11-23       Impact factor: 5.157

2.  Molecular Cloning and Biochemical Characterization of Iron Superoxide Dismutase from Leishmania braziliensis.

Authors:  Camila C B Brito; Fernando V Maluf; Gustavo M A de Lima; Rafael V C Guido; Marcelo S Castilho
Journal:  Mol Biotechnol       Date:  2018-08       Impact factor: 2.695

3.  Enalapril in Combination with Benznidazole Reduces Cardiac Inflammation and Creatine Kinases in Mice Chronically Infected with Trypanosoma cruzi.

Authors:  Arlete Rita Penitente; Ana Luísa Junqueira Leite; Guilherme de Paula Costa; Deena Shrestha; Aline Luciano Horta; Antônio J Natali; Clóvis A Neves; Andre Talvani
Journal:  Am J Trop Med Hyg       Date:  2015-09-08       Impact factor: 2.345

4.  Induction of proinflammatory cytokines and nitric oxide by Trypanosoma cruzi in renal cells.

Authors:  Gabriel M de Oliveira; Nobuko Yoshida; Elisa M S Higa; Sérgio Shenkman; Monique Alves; Daniela Staquicini; Cynthia Cascabulho; Nestor Schor
Journal:  Parasitol Res       Date:  2011-02-17       Impact factor: 2.289

Review 5.  Modulation of immune response in experimental Chagas disease.

Authors:  Beatriz Basso
Journal:  World J Exp Med       Date:  2013-02-20

Review 6.  Immunological cells and functions in Gaucher disease.

Authors:  Manoj Kumar Pandey; Gregory A Grabowski
Journal:  Crit Rev Oncog       Date:  2013

7.  Nigella sativa oil entrapped polycaprolactone nanoparticles for leishmaniasis treatment.

Authors:  Emrah Sefik Abamor; Ozlem Ayse Tosyali; Melahat Bagirova; Adil Allahverdiyev
Journal:  IET Nanobiotechnol       Date:  2018-12       Impact factor: 1.847

8.  Pathogenesis of Chagas disease: time to move on.

Authors:  Fabiana S Machado; Kevin M Tyler; Fatima Brant; Lisia Esper; Mauro M Teixeira; Herbert B Tanowitz
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

Review 9.  Nano-Medicines a Hope for Chagas Disease!

Authors:  Satabdi Datta Choudhury
Journal:  Front Mol Biosci       Date:  2021-06-01

10.  Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi.

Authors:  Raquel Tayar Nogueira; Alanderson Rocha Nogueira; Mirian Claudia Souza Pereira; Maurício Martins Rodrigues; Patrícia Cristina da Costa Neves; Ricardo Galler; Myrna Cristina Bonaldo
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.